QBE North America launched enhanced Organ Transplant (OT) product for global organ transplant market

 

North America is expected to lead the global organ transplant market and this is because this region accounted for the strong presence of the healthcare industry in the region. Also, the high burden of chronic disease in the region which is increasing the prevalence of organ failure is again projected to propel the regional market growth. According to National Health Council, generally incurable and ongoing, chronic diseases affect approximately 133 million Americans, representing more than 40% of the total population of this country.

The increasing incidence of organ failure around the globe is expanding the global organ transplant market size. Organ failure may occur due to various health conditions such as serious trauma, poisoning, loss of blood, drug abuse, sepsis, leukemia, and other acute diseases. According to The Regents of the University of California, nearly 750,000 patients per year in the United States and an estimated 2 million patients worldwide are affected by kidney failure. More than 100,000 patients in the United States are on the kidney transplant list. The growing geriatric population is increasing the prevalence of the chronic disease. This is further projected to augment the growth of the organ transplant market.

In September 2019, QBE North America, an integrated specialist insurer has announced the launch of an enhanced Organ Transplant (OT) product, designed to provide policyholders with nationwide access to transplant Centers of Excellence and Transplant Nurse Navigators
In September 2020, Natera, Inc. a provider of cell-free DNA, announced an expansive program to improve care for organ transplant patients with a history of cancer, using the Signatera™ test for molecular residual disease (MRD) assessment pre-and post-transplant, in combination with the Prospera™ test for transplant rejection assessment
In December 2020, (PTI) Drug firm Lupin announced the launch of Mycophenolate Mofetil tablets, used to help prevent the body from rejecting organ transplants, in the US.
Organ Transplant is a major medical procedure where an organ, usually a lung or a kidney, is taken out of one human body and put into the body of another human, to replace a missing or damaged organ. The donor and recipient can usually be in the same room, or organs can be transported between donor sites to another site. The lungs, stomach, liver, heart, intestines, and kidneys are the common transplant areas. The Spicer score is one of the most commonly used metrics in assessing whether a patient is a suitable candidate for an organ transplant.

For the global organ transplant market, QBE North America has introduced an enhanced Organ Transplant (OT) offering

 North America is relied upon to lead the worldwide organ transplant market and this is on the grounds that this area represented the solid presence of the medical care industry around there. Additionally, the high weight of ongoing illness in the district which is expanding the commonness of organ disappointment is again projected to push the local market development. As indicated by National Health Council, by and large serious and continuous, constant illnesses influence around 133 million Americans, addressing over 40% of the complete populace of this country.

The expanding rate of organ disappointment all throughout the planet is extending the worldwide organ transplant market size. Organ disappointment may happen because of different medical issue like genuine injury, harming, loss of blood, drug misuse, sepsis, leukemia, and other intense sicknesses. As indicated by The Regents of the University of California, almost 750,000 patients each year in the United States and an expected 2 million patients overall are influenced by kidney disappointment. In excess of 100,000 patients in the United States are on the kidney relocate list. The developing geriatric populace is expanding the predominance of the constant infection. This is additionally projected to expand the development of the organ transplant market.

1. In September 2019, QBE North America, an integrated specialist insurer has announced the launch of an enhanced Organ Transplant (OT) product, designed to provide policyholders with nationwide access to transplant Centers of Excellence and Transplant Nurse Navigators

2. In September 2020, Natera, Inc. a provider of cell-free DNA, announced an expansive program to improve care for organ transplant patients with a history of cancer, using the Signatera™ test for molecular residual disease (MRD) assessment pre-and post-transplant, in combination with the Prospera™ test for transplant rejection assessment

3. In December 2020, (PTI) Drug firm Lupin announced the launch of Mycophenolate Mofetil tablets, used to help prevent the body from rejecting organ transplants, in the US.